Skip to main content

SureGuide Chemically Synthesized sgRNA

SureGuide Chemically Synthesized sgRNA

Agilent is a world leader in nucleic acid synthesis and is extending our expertise into chemically synthesized long RNA. Using a patented, proprietary chemistry1, Agilent makes the synthesis of long RNA oligonucleotides as robust and efficient as DNA synthesis. Agilent uses this chemistry to synthesize and deliver high quality CRISPR guides, and our processing provides guides with few contaminants.

Agilent researchers have developed chemical modifications which improve the efficiency, stability, and specificity of guide RNAs in a variety of cell types. These modifications are patent pending and are available in a variety of options. 2,3

Request a Quote for Your Sequences

Design your own guide RNA!

Design your own guide RNA!

Design your own guide RNA with Agilent's SureDesign tool. Register for free, create your design in only a few minutes, and upload your RNA guide sequence to receive a quote!

Request a Quote for Your Sequences

Why choose Agilent's SureGuide Chemically Synthesized sgRNAs?

  • Custom sequences up to 160 nt
  • Quantities from 100 µg to 100 mg (3-3000 nmol)
  • Research and Development grade to GMP material
  • Chemical modifications at no extra charge (M or MS at 5' and 3' ends)
  • Additional modifications and longer lengths available upon request

Request more information

Discover more of Agilent's CRISPR products

Learn more

For Research Use Only. Not for use in diagnostic procedures.

(1) Douglas J. Dellinger, Zoltán Timár, Joel Myerson, Agnieszka B. Sierzchala,John Turner, Fernando Ferreira, Zoltán Kupihár, Geraldine Dellinger,Kenneth W. Hill, James A. Powell, Jeffrey R. Sampson, and Marvin H. Caruthers. Streamlined Process for the Chemical Synthesis of RNA Using 2'-O-Thionocarbamate-Protected Nucleoside Phosphoramidites in the Solid Phase, J. Am. Chem. Soc. 133, 11540–11556 (2011). DOI: 10.1021/ja201561z

(2) Ayal Hendel, Rasmus O Bak, Joseph T Clark, Andrew B Kennedy, Daniel E Ryan, Subhadeep Roy, Israel Steinfeld, Benjamin D Lunstad, Robert J Kaiser, Alec B Wilkens, Rosa Bacchetta, Anya Tsalenko, Douglas Dellinger, Laurakay Bruhn & Matthew H Porteus. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nature Biotechnology, Vol. 33 No. 9 (2015); doi:10.1038/nbt.3290

(3) (3) Daniel E. Ryan, David Taussig, Israel Steinfeld, Smruti M. Phadnis, Benjamin D. Lunstad, Madhurima Singh, Xuan Vuong, Kenji D. Okochi, Ryan McCaffrey, Magdalena Olesiak, Subhadeep Roy, Chong Wing Yung, Bo Curry, Jeffrey R. Sampson, Laurakay Bruhn, and Douglas J. Dellinger. Improving CRISPR–Cas specificity with chemical modifications in single-guide RNAs. Nucleic Acids Research, Vol. 46, No. 2 (2018); doi: 10.1093/nar/gkx1199

Patent Information: US 9,067,961, US 9,273,086, US 9,896,472